The effect of treating with anti-interleukin-1 receptor antibody on the course of experimental murine cutaneous leishmaniasis

• Published in: Parasite immunology Vol. 16; no. 11; p. 571
• Main Authors: Theodos, C M, Shankar, A, Glasebrook, A L, Roeder, W D, Titus, R G
• Format: Journal Article
• Language: English
• Published: England 01.11.1994
• Subjects: Animals; Antibodies, Monoclonal - immunology; Antibodies, Monoclonal - therapeutic use; Cytokines - biosynthesis; Disease Models, Animal; Interleukin-1; Leishmania major; Leishmaniasis, Cutaneous - immunology; Leishmaniasis, Cutaneous - pathology; Leishmaniasis, Cutaneous - therapy; Lymph Nodes - immunology; Lymphocyte Activation; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Parasitemia - drug therapy; Parasitemia - immunology; Receptors, Interleukin-1 - immunology
• ISSN: 0141-9838; 1365-3024
• DOI: 10.1111/j.1365-3024.1994.tb00312.x

To assess the role of interleukin-1 (IL-1) in cutaneous leishmaniasis, Leishmania major-infected mice were treated with an anti-IL-1 receptor monoclonal antibody, LA-15.6. MoAb LA-15.6 prevents binding of IL-1 to both the T cell and B cell/macrophage forms of the IL-1 receptor. We found that treating with LA 15.6 inhibited the development of cutaneous lesions of L. major in both genetically-susceptible and resistant mice. Interestingly, this treatment had little or no effect on parasite numbers in the lesions or on the cytokines (interferon-gamma, interleukin-4) that the animals produced in response to infection with the parasite. These results suggest that although IL-1 plays a detrimental role in cutaneous leishmaniasis, it does not mediate this effect by altering the parasite-specific T cell response.